• César C Carías-Alvarado, Francisco López-Hun, Fabiola Valvert, Juan C Barrios-Menéndez, Alba Kihn-Alarcón, Vicky de Falla, Ximing Xu, and Karla Escobar-Castro.
• Cancer Biological Research Laboratory, Liga Nacional Contra el Cáncer-Instituto de Cancerología, Guatemala, Guatemala.
• Gac Med Mex. 2022 Jan 1; 158 (2): 788278-82.

IntroductionThe study of anti-SARS-CoV-2 IgG antibodies allows asymptomatic individuals with COVID-19 to be identified, and post-infection and post-vaccination immunity status to be evaluated.ObjectiveTo know the behavior of anti-SARS-CoV-2 IgG antibodies before and after vaccination in workers of a cancer center.MethodsPrior to the application of the vaccine, the presence of anti-SARS-CoV-2 IgG antibodies (n = 171) was analyzed by evaluating anti-N IgG antibodies; post-vaccination, after receiving the second dose, anti-S IgG antibodies were evaluated (n = 60).ResultsPrior to vaccination, IgG antibodies were present in 18.71% of participants; they were detected in 65.22% of those with prior history of COVID-19 diagnosis and in 11.49% of those without it. The positions with the highest prevalence were nurses (28.26%), paramedics (27.59%) and administrative workers (27.78%), p < 0.01. Anosmia, ageusia and chest tightness were associated with the presence of IgG (p < 0.05). Post-vaccination, all participants developed IgG antibodies; people with a previous COVID-19 diagnosis had higher titers: 10,277 vs. 6,819 AU/mL, p < 0.001.ConclusionsThe study of anti-SARS-CoV-2 IgG antibodies allowed asymptomatic health workers to be identified. A high percentage of participants with prior COVID-19 diagnosis had antibodies. All participants developed IgG antibodies after vaccination, with higher titers being identified in those with previous infection.Copyright: © 2022 Permanyer.

14 keywords...

hide…